annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 17A An advanced computerized decision support technology to support breast
multidisciplinary meetings. (Abstract #658)
V. Patkar, D. Acosta, T. Davidson, A. Jones, J. Fox, M. R. Keshtgar
Brd. 17B Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in
HER2 nonamplified (non-amp) breast cancer (BC) cells. (Abstract #659)
D. M. Collins, N. O’Donovan, J. Dean, A. E. Hogan, J. Ballot, D. McDonnell,
A. O’Meara, J. Crown
Brd. 17C The influence of the 21-gene recurrence score assay on decision making
about adjuvant chemotherapy in stage I-II estrogen receptor-positive breast
cancer: Experience at a single center with a uniform treatment policy.
(Abstract #660)
D. B. Geffen, S. Abu-Ghanem, N. Sion-Vardy, R. Braunstein, M. Tokar, S. Ariad,
B. Delgado, M. Bayme, M. Koretz
Brd. 17D Prognostic relationship of SATB1 gene expression and estrogen receptor
status in breast cancer cells. (Abstract #661)
L. Mavrova, T. Karn, L. Hanker, E. Ruckhäberle, V. Mueller, U. Holtrich,
M. Kaufmann, A. Rody
Brd. 17E Differential response from neoadjuvant chemotherapy across breast cancer
subtypes. (Abstract #662)
H. Jinno, S. Matsuda, T. Hayashida, M. Takahashi, M. Sakata, T. Ikeda, M. Mukai,
Y. Kitagawa
Brd. 17F Local effects of tamoxifen versus aromatase inhibitors (AI) on breast tissue:
A longitudinal dynamic contrast enhanced (DCE) breast MRI cohort study.
(Abstract #663)
C. K. Kuhl, S. Schrading, W. Kuhn, H. H. Schild
Brd. 17G Microscopic disease after neoadjuvant therapy in inflammatory breast
cancer. (Abstract #664)
A. Lodhi, K. Mosalpuria, S. Krishnamurthy, S. Jackson, C. Hall, E. Andreopoulou,
B. Singh, V. Valero, A. Lucci
Brd. 17H Efficacy of capecitabine (C)-based therapy in patients with first-line
metastatic breast cancer (MBC) previously treated with adjuvant
anthracyclines and taxanes. (Abstract #665)
F. Siedentopf, W. Schoenegg, M. Kaufmann, M. Debled, N. J. Robert
Brd. 18A Timing of genetic testing relative to breast cancer surgery. (Abstract #666)
J. R. Trosman, C. B. Weldon, W. J. Gradishar, J. C. Schink
Brd. 18B Assessment of concomitant versus sequential aromatase inhibitor with
radiotherapy for postmenopausal women with early-stage breast cancer.
(Abstract #667)
N. M. Abd El-Bary, T. Hashem
Brd. 18C HER2-positive early breast cancers: What proportion are receiving adjuvant
trastuzumab therapy? A multicenter audit. (Abstract #668)
S. Marla, J. Cardale, D. J. Dodwell, A. Skene, O. Gojis, C. Palmieri, P. Abram,
S. Cleator, A. Bowman, J. C. Doughty
Brd. 18D The effects of Oncotype DX recurrence scores on chemotherapy receipt in a
multi-institutional breast cancer cohort. (Abstract #669)
F. O. Ademuyiwa, A. Miller, S. B. Edge, M. A. Thorat, G. W. Sledge, S. S. Badve
Brd. 18E A multicenter study to determine the optimum duration of neoadjuvant
letrozole on tumor regression to permit breast-conserving surgery: Final
analyses. (Abstract #670)
R. Carpenter, J. C. Doughty, C. Cordiner, N. Moss, A. Gandhi, C. Wilson,
C. Andrews, G. Gui, A. Skene
Brd. 18F Nasal septum perforations: A side effect of the association of bevacizumab
and taxanes in patients with breast cancer? (Abstract #671)
A. Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, J. Bonneterre
156